ERBB3 and ovarian cancer: A study found that a DNA-damaging agent, doxorubicin-induced HER3-PI3K-AKT signaling in ovarian cancer cells, and a combination of HER3 inhibition and doxorubicin reported increased apoptosis in the chemoresistant cells [115].